Source: Annual Congress 2009 - Pulmonary circulation
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
B. Degano, O. Sitbon, G. Garcia, X. Jais, L. Savale, D. Natali, M. Humbert, G. Simonneau (Clamart, France). Patients walking more than 450 m in 6 minutes at diagnosis of pulmonary arterial hypertension: baseline characteristics and prognostic factors. Eur Respir J 2009; 34: Suppl. 53, 1893

Member's Comments

No comment yet.

Related content which might interest you: Predictive value of 6 MWD and derived indices 3 months after initial PAH therapy for the necessity of a combination therapy in patients with pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Pulmonary pressure at rest and during slight exercise might have prognostic relevance in patients at risk for pulmonary arterial hypertension Source: Annual Congress 2008 - Pulmonary arterial hypertension and other pulmonary vascular diseases Year: 2008 Incapacity to increase pulmonary blood flow determines 6 minutes walking distance in pulmonary hypertension Source: Annual Congress 2011 - Physiology of human pulmonary hypertension Year: 2011 Exercise testing to predict outcome in idiopathic versus associated pulmonary arterial hypertension Source: Eur Respir J 2012; 40: 1410-1419 Year: 2012 Risk stratification and prognostic factors in patients with pulmonary arterial hypertension and comorbidities Source: Virtual Congress 2020 – Clinical evaluation, biomarkers and risk assessment of pulmonary hypertension Year: 2020 Effects of sildenafil on 6-minute walk distance (6MWD) and WHO functional class (FC) in pulmonary arterial hypertension (PAH) patients after 1 year of treatment Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension Year: 2005 Clinical, functional and hemodynamic response after six months of sildenafil in patients with pulmonary arterial hypertension Source: Annual Congress 2007 - Pulmonary circulation Year: 2007 The value of cardiopulmonary exercise test in assessment of the severity of pulmonary arterial hypertension patients Source: International Congress 2017 – Exercise and physiology in pulmonary hypertension Year: 2017 Smoking history and pulmonary arterial hypertension (PAH) onset and clinical outcomes (REVEAL) Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020 Stroke volume reflects changes in six minute walk test during follow-up in pulmonary arterial hypertension Source: Annual Congress 2009 - Pulmonary circulation I Year: 2009 Cardiopulmonary exercise test unveils abnormal exercise physiology in patients affected by pulmonary arterial hypertension with a low-risk profile 6 minute walk distance. Source: Virtual Congress 2020 – Exercise and haemodynamics in pulmonary hypertension Year: 2020 Is 6-minute walk distance (6MWD) associated with long-term outcomes in pulmonary arterial hypertension (PAH)? Results from SERAPHIN Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment Year: 2013 Baseline profile of patients initiating sitaxentan for pulmonary arterial hypertension (PAH): preliminary results from thelin outcomes for patients surveillance (TOPS) Source: Annual Congress 2008 - Pulmonary hypertension II Year: 2008 The prognostic value of percent predicted six-minute walk distance in pulmonary arterial hypertension Source: Annual Congress 2009 - Clinical management of pulmonary arterial hypertension Year: 2009 6MWD in patients with pulmonary arterial hypertension (PAH) Source: Eur Respir J 2003; 22: Suppl. 45, 464s Year: 2003 Risk factors for elevated liver function tests (eLFTs) in patients with pulmonary arterial hypertension (PAH) treated with sitaxentan and followed in a European safety registry Source: Annual Congress 2011 - Experimental pulmonary hypertension Year: 2011 Prognostic value of hemodynamics following treatment initiation in pulmonary arterial hypertension Source: International Congress 2017 – Cardiac function assessment in pulmonary hypertension Year: 2017 Hemodynamics as a substitute for exercise capacity endpoints in patients with pulmonary arterial hypertension (PAH): A model based assessment for sildenafil Source: Annual Congress 2010 - Present and future medical management of pulmonary arterial hypertension Year: 2010 Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience Source: Eur Respir Rev 2017; 26: 160055 Year: 2017 Impact of the state of endothelium on clinical and functional parameters in COPD patients with arterial hypertension. Source: International Congress 2017 – Novel mechanisms and treatments for COPD Year: 2017